media – Page 5 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Fosun Pharma and Jiuyuan Gene Sign Exclusive Overseas Commercialization Agreement for Multiple Biological Drugs and Innovative Medical Devices

The reporter learned from Fosun Pharma on May 28 that the company recently reached an agreement with Jiuyuan Gene on a number of biological drugs and innovative drugs.A signing ceremony for the exclusive overseas commercialization rights cooperation of medical products was held in Hangzhou. According to the agreement, Fosun Pharma obtained exclusive authorization from Jiuyuan Gene for the exclusive clinical development, registration, production and commercialization rights of products such as semaglutide, Bone Youdao and JY-23 in all countries in the Middle East and North Africa, sub-Saharan Africa and some ASEAN countries. Chen Yuqing, Chairman of Fosun Pharma, said: “We are very pleased to work with Jiuyuan Gene to promote the development and commercialization of multiple biopharmaceuticals and innovative medical devices in overseas markets. This cooperation is not only a deep synergy of the technical strength and resource endowment of both parties, but also aThis is another important milestone in our ...
- Source: drugdu
- 51
- June 2, 2025
Mesutoclax, a novel BCL2 inhibitor, is approved for clinical trials in the treatment of myelodysplastic syndrome

On May 29, InnoCare Pharma announced that the company’s independently developed new BCL2 inhibitor Mesutoclax (ICP-248) combined with azacitidine was approved by the National Medical Products Administration (NMPA) Drug Review Center (CDE) to conduct clinical studies for the treatment of myeloid malignancies, including but not limited to myelodysplastic syndrome (MDS). It is understood that ICP-248 is a new oral, highly selective BCL2 inhibitor. BCL2 is an important regulatory protein in the cell apoptosis pathway, and its abnormal expression is associated with the occurrence and development of a variety of malignant blood tumors. ICP-248 selectively inhibits BCL2 and restores the programmed cell death mechanism of tumor cells, thereby exerting anti-tumor efficacy. Myelodysplastic syndrome (MDS) is a myeloid neoplasm characterized by clonal proliferation of hematopoietic stem cells, recurrent genetic abnormalities, myeloid cell dysplasia, ineffective hematopoiesis, peripheral blood cell reduction, and a high risk of transformation to acute myeloid leukemia (AML). Approximately one-third ...
- Source: drugdu
- 46
- June 2, 2025
Humanwell Pharmaceuticals’ RFUS-949 tablet clinical trial approved

On May 29, Humanwell Pharmaceutical issued an announcement that its holding subsidiary Yichang Renfu Pharmaceutical Co., Ltd. recently received the “Drug Clinical Trial Approval Notice” for RFUS-949 tablets approved and issued by the National Medical Products Administration, agreeing to conduct clinical trials of this product for acute and chronic pain. RFUS-949 is a new molecular entity developed by Yichang Renfu, and is registered as a Class 1 chemical drug. RFUS-949 tablets are intended to be used clinically for the treatment of acute and chronic pain. Currently, no similar products have been approved for marketing in China. So far, Yichang Renfu’s cumulative R&D investment in this project is approximately RMB 15 million. In the first quarter of 2025, Renmin Pharmaceutical achieved revenue of 6.137 billion yuan and net profit attributable to shareholders of the parent company of 540 million yuan. https://finance.eastmoney.com/a/202505293417929589.html
- Source: drugdu
- 57
- May 31, 2025
The clinical trial of STC007 injection of Sunshine Novo’s subsidiary has achieved the expected goal

May 29, Sunshine Novo(688621) issued an announcement that the Phase II clinical trial of STC007 injection independently developed by the company’s wholly-owned subsidiary Novo Shengtai for the treatment of moderate to severe pain after abdominal surgery has achieved the expected goals. The clinical trial involved 156 subjects and mainly evaluated the efficacy, safety and pharmacokinetic characteristics of STC007 injection. The results showed that STC007 injection significantly improved the pain scores of subjects within 0-24 hours after surgery, and performed better than the control group in terms of the amount of rescue treatment drugs used and the time to first rescue treatment. In terms of safety, the overall safety and tolerability of STC007 injection were good, no new safety signals were found, and no serious adverse events occurred .Due to the high risk of R&D, investors need to make careful decisions. In the first quarter of 2025, Sunshine Novo achieved revenue ...
- Source: drugdu
- 55
- May 31, 2025
The National Medical Products Administration conditionally approved the marketing of Trastuzumab for injection

According to the website of the National Medical Products Administration, the National Medical Products Administration has recently conditionally approved the marketing of Ruikang Trastuzumab for Injection (trade name: Avida) submitted by Suzhou Shengdia Biopharmaceutical Co., Ltd. through the priority review and approval procedure. The single drug is suitable for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have HER2 (ERBB2) activating mutations and have received at least one systemic treatment in the past. The launch of this product provides a new treatment option for related patients. https://finance.eastmoney.com/a/202505293418294646.html
- Source: drugdu
- 49
- May 31, 2025
Moderna withdraws its application for the launch of the new crown/influenza combined vaccine, and its share price fell more than 6% during the session

On Wednesday, US Eastern Time, American vaccine manufacturer Moderna announced that it had withdrawn its application for marketing authorization for the combined COVID-19 and influenza vaccine to wait for more efficacy data of its vaccine. Affected by this news, its stock price fell by more than 6% during the trading session. Moderna said it will resubmit its application later this year with effectiveness data from its standalone flu vaccine in a large-scale trial, which is expected to be released this summer. Earlier this month, Moderna claimed, largely as expected, that it did not expect regulators to approve the vaccine until 2026 because more data on its flu vaccine was needed. It is worth noting that the day before Moderna made this decision, the United States tightened the approval requirements for the new crown vaccine. The U.S. Food and Drug Administration (FDA) said that the approval of new crown vaccines for ...
- Source: drugdu
- 47
- May 31, 2025
Jimin Health’s hospitals and Dabo Biotech signed a strategic cooperation agreement to expand the layout of cell and gene therapy pipeline

On the evening of May 29, Jimin HealthManagement Co., Ltd. (hereinafter referred to as ” Jimin Health “) issued an announcement that on May 28, 2025, the company’s Boao International Hospital and Guangzhou Dabo Biological ProductsCo., Ltd. (hereinafter referred to as “Dabao Bio”) signed the “Strategic Cooperation Framework Agreement”. Founded in May 2001 and headquartered in Huangpu District, Guangzhou, Dabo Bio is a national high-tech enterprise focusing on anti-tumor gene therapy, immune cell therapy and regenerative medicine. The announcement shows that the “Strategic Cooperation Framework Agreement” mainly covers the following four aspects: first, to promote the clinical research and translational application of new biomedical technologies such as cell and gene therapy; second, to achieve the improvement of scientific research conditions and resource sharing; third, to carry out talent exchange and training; and fourth, to promote the coordinated development of the industrial chain. It is reported that the development of cell ...
- Source: drugdu
- 49
- May 31, 2025
Bivalent HPV is hit hard! Wantai Biopharmaceuticals’ vaccine volume and price both fell, betting on nine-valent may become the last trump card

In the past two years, Wantai Bio ‘s performance data has fallen off a cliff, hitting a new low since its listing. The once “star enterprise” of vaccines is experiencing the most severe performance winter in history. The core driver of the sharp drop in performance is the “big decline” in the vaccine business. Wantai Biological , which once seized the market with the first domestically produced bivalent HPV vaccine “Xinkening” , is now facing the impact of the entry of competitors such as Watson Biological and the expansion of the age range of Merck’s nine-valent vaccine squeezing the market. Faced with difficulties, Wantai Biopharmaceuticals is pinning its hopes on the nine-valent HPV vaccine, which has not yet been approved for marketing. However, this vaccine, which is planned to be a “blockbuster product”, will have to face dual competition from Merck’s “Gardasil 9” (which already covers men) and Watson Biopharmaceuticals ...
- Source: drugdu
- 64
- May 30, 2025
The United States will no longer recommend routine COVID-19 vaccinations for healthy children and pregnant women

On May 27th local time, Robert F. Kennedy Jr., Secretary of the U.S. Department of Health and Human Services (HHS), announced that routine COVID-19 vaccination will no longer be recommended for healthy children and pregnant women. The U.S. Centers for Disease Control and Prevention (CDC) previously recommended that all infants 6 months and older should be vaccinated against the new coronavirus. Just a week ago, the U.S. Food and Drug Administration (FDA) announced that the agency plans to limit the use of the new crown vaccine to the elderly, children and adults with underlying medical conditions. The FDA last week released new regulatory guidance for future COVID-19 vaccine boosters, setting stricter approval standards for vaccination of healthy Americans. The FDA said that vaccines developed against new variants need to be re-approved before they can be marketed. Previously, the FDA usually approved the new crown vaccine for vaccination in all Americans ...
- Source: drugdu
- 55
- May 30, 2025
Kangtai Biological’s trivalent influenza vaccine clinical trial application accepted

On May 28, Kangtai Biological (300601) issued an announcement that it had received an acceptance notice issued by the National Medical Products Administration today, agreeing to accept the clinical trial application for the trivalent influenza virus split vaccine (MDCK cells) jointly developed by the company and Lanzhou Bailing Biotechnology Co., Ltd. The vaccine is suitable for people aged 3 years and above and is intended to stimulate the body to produce immunity against influenza viruses to prevent influenza caused by related types of influenza viruses. In the first quarter of 2025, Kangtai Biological achieved revenue of 645 million yuan and net profit attributable to shareholders of the parent company of 22.43 million yuan. https://finance.eastmoney.com/a/202505283416827087.html
- Source: drugdu
- 51
- May 30, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.